… Dimethyl fumarate (DMF) is approved for the treatment of relapsing–remitting multiple
sclerosis (MS) and has been on the Italian commercial market since January 2015. The efficacy …

… We present the results of a multi-centre study conducted at … In particular, this often occurred
in multiple sclerosis patients … brainstem lesions due to multiple sclerosis with bulbar signs …

… which has been associated with risk of multiple sclerosis. Therefore, targeting of these cells
might disrupt processes in multiple sclerosis pathogenesis. Studies of rituximab—a chimeric …

Background and Objectives: We evaluated clinical and conventional MRI features of a large
population of patients with non-disabling MS to identify potential markers of a benign …

… Although no therapeutic randomized clinical trials were conducted in pediatric cohorts,
open-label multi-center studies reported efficacy and safety results with beta interferons, …

… In two seropositive cases, the patient's father had reportedly suffered from "multiple sclerosis".
A chronic inflammatory CNS disease was also suspected in the grandmother and in the …

… Nevertheless, the present study reports, for the first time, broader data on extrarenal … in
systemic sclerosis patients with stable extrarenal involvement. The multicentre nature of our study …

… The estimated annual RNFL loss in multiple sclerosis amounts to 2 μm using time domain
OCT. The recognition of measurement artifacts exceeding this limit is relevant for the …

… as an off-label treatment option for multiple sclerosis (MS). … study adds to the published
literature confirming that RTX is effective and relatively safe in the treatment of multiple sclerosis…

… relevance in clinically isolated syndrome suggestive of multiple sclerosis remains uncertain.
… We selected 30 patients and 10 healthy controls from our ongoing prospective multicentre …